Literature DB >> 19829371

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.

Richard J Perrin1, Anne M Fagan, David M Holtzman.   

Abstract

Alzheimer's disease affects millions of people around the world. Currently, there are no treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's disease is characterized by protein misfolding in the brain. This process and the associated brain damage begin years before the substantial neurodegeneration that accompanies dementia. Studies using new neuroimaging techniques and fluid biomarkers suggest that Alzheimer's disease pathology can be detected preclinically. These advances should allow the design of new clinical trials and early mechanism-based therapeutic intervention.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19829371      PMCID： PMC2810658          DOI： 10.1038/nature08538

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


  73 in total

1.  Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Authors:  G Chételat; B Desgranges; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

2.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

3.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

4.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

5.  Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.

Authors:  D P Devanand; G Pradhaban; X Liu; A Khandji; S De Santi; S Segal; H Rusinek; G H Pelton; L S Honig; R Mayeux; Y Stern; M H Tabert; M J de Leon
Journal:  Neurology       Date:  2007-03-13       Impact factor: 9.910

6.  Complement activation in very early Alzheimer disease.

Authors:  H Zanjani; C E Finch; C Kemper; J Atkinson; D McKeel; J C Morris; J L Price
Journal:  Alzheimer Dis Assoc Disord       Date:  2005 Apr-Jun       Impact factor: 2.703

Review 7.  Searching for a baseline: functional imaging and the resting human brain.

Authors:  D A Gusnard; M E Raichle; M E Raichle
Journal:  Nat Rev Neurosci       Date:  2001-10       Impact factor: 34.870

Review 8.  Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.

Authors:  Erik Portelius; Henrik Zetterberg; Johan Gobom; Ulf Andreasson; Kaj Blennow
Journal:  Expert Rev Proteomics       Date:  2008-04       Impact factor: 3.940

9.  Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.

Authors:  Ahmadul Kadir; Niels Andreasen; Ove Almkvist; Anders Wall; Anton Forsberg; Henry Engler; Göran Hagman; Marie Lärksäter; Bengt Winblad; Henrik Zetterberg; Kaj Blennow; Bengt Långström; Agneta Nordberg
Journal:  Ann Neurol       Date:  2008-05       Impact factor: 10.422

10.  Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment.

Authors:  Rita João Guerreiro; Isabel Santana; José Miguel Brás; Beatriz Santiago; Artur Paiva; Catarina Oliveira
Journal:  Neurodegener Dis       Date:  2007-10-09       Impact factor: 2.977
View more
  247 in total

1.  Regulation of tau pathology by the microglial fractalkine receptor.

Authors:  Kiran Bhaskar; Megan Konerth; Olga N Kokiko-Cochran; Astrid Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Neuron       Date:  2010-10-06       Impact factor: 17.173

2.  A gene expression phenotype in lymphocytes from Friedreich ataxia patients.

Authors:  Giovanni Coppola; Ryan Burnett; Susan Perlman; Revital Versano; Fuying Gao; Heather Plasterer; Myriam Rai; Francesco Saccá; Alessandro Filla; David R Lynch; James R Rusche; Joel M Gottesfeld; Massimo Pandolfo; Daniel H Geschwind
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

3.  Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study.

Authors:  Karen S SantaCruz; Joshua A Sonnen; Maryam Kherad Pezhouh; Mark F Desrosiers; Peter T Nelson; Suzanne L Tyas
Journal:  J Neuropathol Exp Neurol       Date:  2011-10       Impact factor: 3.685

Review 4.  Episodic memory on the path to Alzheimer's disease.

Authors:  Michela Gallagher; Ming Teng Koh
Journal:  Curr Opin Neurobiol       Date:  2011-11-11       Impact factor: 6.627

5.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

6.  Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Val Lowe; Kejal Kantarci; Matt A Bernstein; Matthew L Senjem; Jeffrey L Gunter; Bradley F Boeve; John Q Trojanowski; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; David S Knopman
Journal:  Arch Neurol       Date:  2012-07

7.  ApoE4 Accelerates Early Seeding of Amyloid Pathology.

Authors:  Chia-Chen Liu; Na Zhao; Yuan Fu; Na Wang; Cynthia Linares; Chih-Wei Tsai; Guojun Bu
Journal:  Neuron       Date:  2017-12-06       Impact factor: 17.173

Review 8.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

9.  Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain.

Authors:  Ian Diner; Jeromy Dooyema; Marla Gearing; Lary C Walker; Nicholas T Seyfried
Journal:  Bioconjug Chem       Date:  2017-09-22       Impact factor: 4.774

Review 10.  Extracellular Zn2+-Dependent Amyloid-β1-42 Neurotoxicity in Alzheimer's Disease Pathogenesis.

Authors:  Yuichi Sato; Mako Takiguchi; Haruna Tamano; Atsushi Takeda
Journal:  Biol Trace Elem Res       Date:  2020-04-13       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.